Entrectinib in patients with advanced or metastatic NTRK fusion- positive solid tumours: integrated analysis of three phase 1-2 trials (vol 21, pg 271, 2020)

被引：0
|
作者：
Doebele, R. C.
Drilon, A.
Paz-Ares, L.
机构：
来源：
LANCET ONCOLOGY | 2020年 / 21卷 / 08期
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
引用
收藏
页码：E372 / E372
页数：1
相关论文
共 50 条
  • [31] Entrectinib in Neurotropic Tropomyosin Receptor Kinase Fusion Positive (NTRK-FP) Gastrointestinal (GI) Cancers: Integrated Analysis of Patients (PTS) Enrolled in Three Trials (STARTRK-2, STARTRK-1, and ALKA-372-001)
    Folprecht, Gunnar
    Siena, Salvatore
    Demetri, George
    Doebele, Robert
    Chae, Young Kwang
    Conkling, Paul
    Garrido-Laguna, Ignacio
    Garrido, Pilar
    Rolfo, Christian
    Sigal, Darren
    Huang, Xinhui
    Simmons, Brian
    Ye, Chenglin
    Ciardiello, Fortunato
    ONCOLOGY RESEARCH AND TREATMENT, 2020, 43 : 135 - 136
  • [32] Updated efficacy and safety of entrectinib in patients with NTRK fusion-positive tumors: Integrated analysis of STARTRK-2, STARTRK-1 and ALKA-372-001
    Rolfo, C.
    Dziadziuszko, R.
    Doebele, R. C.
    Demetri, G.
    Simmons, B.
    Huang, X.
    Ye, C.
    Paz-Ares, L.
    ANNALS OF ONCOLOGY, 2019, 30
  • [33] Entrectinib in locally advanced/metastatic ROS1 and NTRK fusion-positive non-small cell lung cancer (NSCLC): Updated integrated analysis of STARTRK-2, STARTRK-1 and ALKA-372-001
    De Braud, F. G. M.
    Siena, S.
    Barlesi, F.
    Drilon, A.
    Simmons, B. P.
    Huang, X.
    Ye, C.
    Doebele, R. C.
    ANNALS OF ONCOLOGY, 2019, 30 : 609 - 609
  • [34] Patient-reported outcomes from STARTRK-2: a global phase II basket study of entrectinib for ROS1 fusion-positive non-small-cell lung cancer and NTRK fusion-positive solid tumours
    Paz-Ares, L.
    Barlesi, F.
    Siena, S.
    Ahn, M-J
    Drilon, A.
    Conley, A.
    Rolfo, C.
    Wolf, J.
    Seto, T.
    Doebele, R.
    Kapre, A.
    Chen, D.
    McCallum, S.
    Osborne, S.
    Demetri, G.
    ESMO OPEN, 2021, 6 (03)
  • [35] Entrectinib in locally advanced/metastatic ROS1 and NTRK fusion-positive non-small cell lung cancer (NSCLC): Updated integrated analysis of STARTRK-2, STARTRK-1 and ALKA-372-001
    de Braud, F.
    Siena, S.
    Barlesi, F.
    Drilon, A.
    Simmons, B.
    Huang, X.
    Osborne, S.
    Doebele, R. C.
    ANNALS OF ONCOLOGY, 2019, 30
  • [36] Updated analysis of entrectinib in a subset of Chinese (mainland China, Hong Kong, Taiwan) patients (pts) with NTRK fusion-positive (fp) solid tumours and ROS1-fp nonsmall cell lung cancer (NSCLC)
    Lu, S.
    Fan, Y.
    Chiu, C-H.
    Yu, Y.
    Loong, H. H. F.
    Lin, C-C.
    Dong, X.
    Li, J.
    Zhao, J.
    Zhang, Z.
    Zhao, N.
    Xu, T.
    Hou, M.
    Wang, D.
    Hu, X.
    ANNALS OF ONCOLOGY, 2022, 33 : S1536 - S1536
  • [37] CRESTONE: A Phase 2 study of seribantumab in adult patients with neuregulin-1 (NRG1) fusion positive locally advanced or metastatic solid tumors
    Patil, Tejas
    Carrizosa, Daniel R.
    Burkard, Mark E.
    Reckamp, Karen L.
    Desai, Jayesh
    Chae, Young Kwang
    Liu, Stephen V.
    Konduri, Kartik
    Gadgeel, Shirish M.
    Lin, Jessica J.
    Cheema, Parneet K.
    Spigel, David R.
    Schram, Alison M.
    Jansen, Valerie M.
    Elamin, Yasir Y.
    CANCER RESEARCH, 2023, 83 (08)
  • [38] Entrectinib in NTRK fusion-positive non-small cell lung cancer (NSCLC): Integrated analysis of patients (pts) enrolled in STARTRK-2, STARTRK-1 and ALKA-372-001
    Paz-Ares, L.
    Doebele, R. C.
    Farago, A. F.
    Liu, S. V.
    Chawla, S. P.
    Tosi, D.
    Blakely, C. M.
    Krauss, J. C.
    Sigal, D.
    Bazhenova, L.
    John, T.
    Besse, B.
    Wolf, J.
    Seto, T.
    Chow-Maneval, E.
    Ye, C.
    Simmons, B.
    Demetri, G. D.
    ANNALS OF ONCOLOGY, 2019, 30
  • [39] Entrectinib in locally advanced or metastatic ROS1 fusion-positive non-small cell lung cancer (NSCLC): Integrated analysis of ALKA-372-001, STARTRK-1 and STARTRK-2
    Barlesi, F.
    Drilon, A.
    De Braud, F.
    Cho, B. C.
    Ahn, M. J.
    Siena, S.
    Krebs, M. G.
    Lin, C. C.
    John, T.
    Tan, D. S. W.
    Seto, T.
    Dziadziuszko, R.
    Arkenau, H-T.
    Rolfo, C.
    Wolf, J.
    Ye, C.
    Riehl, T.
    Eng, S.
    Doebele, R. C.
    ANNALS OF ONCOLOGY, 2019, 30
  • [40] Entrectinib in locally advanced or metastatic ROS1 fusion-positive non-small cell lung cancer (NSCLC): Integrated analysis of ALKA-372-001, STARTRK-1 and STARTRK-2
    Drilon, Alexander
    Barlesi, Fabrice
    De Braud, Filippo
    Cho, Byoung Chul
    Ahn, Myung-Ju
    Siena, Salvatore
    Krebs, Matthew G.
    Lin, Chia-Chi
    John, Tom
    Tan, Daniel S. W.
    Seto, Takashi
    Dziadziuszko, Rafal
    Arkenau, Hendrick-Tobias
    Rolfo, Christian
    Wolf, Juergen
    Ye, Chenglin
    Riehl, Todd
    Eng, Susan
    Doebele, Robert C.
    CANCER RESEARCH, 2019, 79 (13)
12345